Yulia Y. Maxuitenko

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Adam B. Keeton · 3 shared papers, 1 shared grant, 2019–2026 · strength 1.35
   • Grant Advancing Pan-RAS Inhibitors for Colorectal Cancer Interception: A Dual Approach Integrating Natural Product Drug Disco… R01CA316420↗
   • Paper ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma DOI 10.64898/2026.02.11.705411↗
   • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
2. Gary Anthony Piazza · 3 shared papers, 1 shared grant, 2019–2026 · strength 1.35
   • Grant Advancing Pan-RAS Inhibitors for Colorectal Cancer Interception: A Dual Approach Integrating Natural Product Drug Disco… R01CA316420↗
   • Paper ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma DOI 10.64898/2026.02.11.705411↗
   • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
3. Angela Isabel Calderon · 1 shared grant, 2026 · strength 0.86
   • Grant Advancing Pan-RAS Inhibitors for Colorectal Cancer Interception: A Dual Approach Integrating Natural Product Drug Disco… R01CA316420↗
4. Donald J Buchsbaum · 2 shared papers, 2025–2026 · strength 0.41
   • Paper ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma DOI 10.64898/2026.02.11.705411↗
   • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
5. Sujith Sarvesh · 2 shared papers, 2025–2026 · strength 0.41
   • Paper ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma DOI 10.64898/2026.02.11.705411↗
   • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
6. Dhana Sekhar Reddy Bandi · 2 shared papers, 2025–2026 · strength 0.41
   • Paper ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma DOI 10.64898/2026.02.11.705411↗
   • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
7. Ganji Purnachandra Nagaraju · 2 shared papers, 2025–2026 · strength 0.41
   • Paper ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma DOI 10.64898/2026.02.11.705411↗
   • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
8. Jeremy B. Foote · 2 shared papers, 2025–2026 · strength 0.41
   • Paper ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma DOI 10.64898/2026.02.11.705411↗
   • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
9. Mehmet Akce · 2 shared papers, 2025–2026 · strength 0.41
   • Paper ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma DOI 10.64898/2026.02.11.705411↗
   • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
10. Asfar Sohail Azmi · 2 shared papers, 2025–2026 · strength 0.41
    • Paper ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma DOI 10.64898/2026.02.11.705411↗
    • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
11. Bassel F. El‐Rayes · 2 shared papers, 2025–2026 · strength 0.41
    • Paper ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma DOI 10.64898/2026.02.11.705411↗
    • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
12. Upender Manne Manne · 1 shared paper, 2025 · strength 0.19
    • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
13. Julienne L. Carstens · 1 shared paper, 2025 · strength 0.19
    • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
14. Karina Jin Yoon · 1 shared paper, 2025 · strength 0.19
    • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
15. Alice Domenichini · 1 shared paper, 2019 · strength 0.08
    • Paper Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. DOI 10.1186/s13046-019-1308-7↗
16. Aleksandra Adamska · 1 shared paper, 2019 · strength 0.08
    • Paper Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. DOI 10.1186/s13046-019-1308-7↗
17. Vincenzo De Laurenzi · 1 shared paper, 2019 · strength 0.08
    • Paper Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. DOI 10.1186/s13046-019-1308-7↗
18. Pierluigi Di Sebastiano · 1 shared paper, 2019 · strength 0.08
    • Paper Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. DOI 10.1186/s13046-019-1308-7↗
19. Verena Damiani · 1 shared paper, 2019 · strength 0.08
    • Paper Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. DOI 10.1186/s13046-019-1308-7↗
20. Marco Falasca · 1 shared paper, 2019 · strength 0.08
    • Paper Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. DOI 10.1186/s13046-019-1308-7↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.